<p><img src="https://imageproxy.pbkrs.com/https://www.drugdiscoverytrends.com/wp-content/uploads/2023/04/AdobeStock_577842756-300x195.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.drugdiscoverytrends.com/wp-content/uploads/2023/04/AdobeStock_577842756-300x195.jpg"/></p>
<p>[sizsus/Adobe Stock]</p>
<p>制药行业的传统层级正面临多年来最强烈的挑战，预计 2024 年的收入显示出领导者之间的动态变化。虽然默克（$63.9B）和辉瑞（$62.5B）占据了前两位，但阿斯利康（+17.9%）、礼来（+33.9%）和诺和诺德（+26.1%）的两位数增长则预示着该行业竞争格局的加速转变。</p>
<p>GLP-1 市场的持续强劲仍然是市场的颠覆者，但这些药物在可及性、成本和市场渗透方面也面临复杂的挑战。</p>
<p>阿斯利康在 GLP-1 疗法占据主导地位的市场中成为了一个意外的成功故事。其强大的产品组合和在关键治疗领域的表现帮助推动了前九个月总收入增长 19%，达到 391.82 亿美元。肿瘤学、心血管、肾脏与代谢（CVRM）以及呼吸与免疫学（R&amp;I）的增长率分别为 22%、21% 和 24%，稀有疾病的增长率也达到了 14%。像 Farxiga 和 Enhertu 这样的关键产品在第三季度分别贡献了 34% 和 60% 的增长。阿斯利康还宣布在美国进行 20 亿美元的研发和制造投资，并应对了中国的监管挑战。因此，阿斯利康上调了 2024 年的全年指导，预计总收入和核心每股收益将实现高个位数的百分比增长。</p>
<p>在整体收入方面，默克公司在 2024 年继续保持稳定的轨迹，预计全球销售额在 636 亿美元到 641 亿美元之间，年增长约为 5.8% 到 6.6%。然而，该公司的季度增长已放缓，从第一季度的 12%（不包括外汇影响）降至第三季度的 7%，这表明即使 Keytruda 的销售依然强劲，仍可能面临挑战。辉瑞也在后疫情的复杂过渡中继续前行，但尽管预计由于 COVID-19 产品销售下降，年销售额将下降约 36% 到 39%，该公司在第三季度表现突出。</p>
<p>以下是完整的预测。</p>
<table>
<thead>
<tr>
<th><strong>排名</strong></th>
<th><strong>公司</strong></th>
<th><strong>2023 年收入</strong></th>
<th><strong>2024 年预测</strong></th>
<th><strong>预计增长</strong></th>
<th><strong>关键财务亮点</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>默克</td>
<td>$60.12B</td>
<td>$63.85B</td>
<td>+6.2%</td>
<td>Q1-Q3: 9%, 7%, 4% 增长轨迹；剔除外汇影响的强劲势头（Q1: 12%, Q3: 7%）；指导：$63.6B-$64.1B</td>
</tr>
<tr>
<td>2</td>
<td>辉瑞</td>
<td>$58.50B</td>
<td>$62.50B</td>
<td>+6.8%</td>
<td>Q3 显示恢复：31% 增长；COVID 影响已纳入指导；最近的指导上调：$61.0B-$64.0B</td>
</tr>
<tr>
<td>3</td>
<td>阿斯利康</td>
<td>$45.81B</td>
<td>$54.00B</td>
<td>+17.9%</td>
<td>一致的高个位数增长（Q1-Q3: 19%, 17%, 21%）；年初至今：$39.18B (+19%); 各季度强劲势头。指导在 “高个位数” 范围内。</td>
</tr>
<tr>
<td>4</td>
<td>罗氏</td>
<td>$51.45B</td>
<td>$53.50B</td>
<td>+4.0%</td>
<td>Q1-Q3: 加速增长（2%, 5%, 9%）；年初至今：6% CER 增长；中个位数指导</td>
</tr>
<tr>
<td>5</td>
<td>强生</td>
<td>$50.93B</td>
<td>$53.48B</td>
<td>+5.0%</td>
<td>制药部门稳定在 5.5% 增长</td>
</tr>
<tr>
<td>6</td>
<td>赛诺菲</td>
<td>$46.59B</td>
<td>$52.97B</td>
<td>+13.7%</td>
<td>加速增长（5.7%, 10.2%, 15.7%）；强劲的 Q3：€13.44B；上调每股收益指导</td>
</tr>
<tr>
<td>7</td>
<td>诺华</td>
<td>$45.44B</td>
<td>$49.94B</td>
<td>+9.9%</td>
<td>稳定增长（7%, 9%, 10%）；低双位数指导；强劲的营业收入</td>
</tr>
<tr>
<td>8</td>
<td>百时美施贵宝</td>
<td>$45.01B</td>
<td>$47.44B</td>
<td>+5.4%</td>
<td>一致增长（5%, 9%, 8%）；~5% 收入增长指导；Q2 表现稳健，增长 9%</td>
</tr>
<tr>
<td>9</td>
<td>礼来</td>
<td>$34.12B</td>
<td>$45.70B</td>
<td>+33.9%</td>
<td>市场领先的 Q2/Q3（36%, 20%）；明确的指导：$45.4B-$46.0B；关键产品强劲势头</td>
</tr>
<tr>
<td>10</td>
<td>诺和诺德</td>
<td>$33.71B</td>
<td>$42.50B</td>
<td>+26.1%</td>
<td>Q3: 21% 增长；Wegovy 销售增长 84%；Ozempic 销售增长 28%；指导：23-27% 增长</td>
</tr>
<tr>
<td>11</td>
<td>GSK</td>
<td>$37.73B</td>
<td>$40.23B</td>
<td>+6.6%</td>
<td>强劲的上半年（10%, 13%）；Q3 放缓至 2%；指导：7-9% 营业额增长</td>
</tr>
<tr>
<td>12</td>
<td>安进</td>
<td>$28.19B</td>
<td>$33.30B</td>
<td>+18.1%</td>
<td>一致的 20%+ 增长；Q1-Q3: 22%, 20%, 23%；指导：$32.8B-$33.8B</td>
</tr>
<tr>
<td>13</td>
<td>武田</td>
<td>$30.34B</td>
<td>$30.52B</td>
<td>+0.6%</td>
<td>强劲的上半年：14.1%, 13.4% 增长；上调预测至¥4,480B；优于最初的平稳指导</td>
</tr>
<tr>
<td>14</td>
<td>吉利德</td>
<td>$27.12B</td>
<td>$27.95B</td>
<td>+3.1%</td>
<td>Q3: 7% 增长；关键产品增长（Biktarvy +13%）；指导：$27.8B-$28.1B</td>
</tr>
<tr>
<td>15</td>
<td>拜耳</td>
<td>$17.78B</td>
<td>$17.23B</td>
<td>-3.0%</td>
<td>Q3 挑战：3.6% 收入下降；EBITDA 下降 25.8%；谨慎的 2025 年展望</td>
</tr>
<tr>
<td>16</td>
<td>Teva</td>
<td>$15.85B</td>
<td>$16.30B</td>
<td>+2.8%</td>
<td>Q3: 13% 美元增长；强劲的产品表现；指导：$16.1B-$16.5B</td>
</tr>
<tr>
<td>17</td>
<td>大冢</td>
<td>$14.32B</td>
<td>$15.25B</td>
<td>+6.5%</td>
<td>Q3: 同比增长 17%；¥1,730.1B 预测；积极的利润展望</td>
</tr>
<tr>
<td>18</td>
<td>Viatris</td>
<td>$15.43B</td>
<td>$15.05B</td>
<td>-2.5%</td>
<td>Q3: 3% 增长（剔除剥离影响）；指导：$14.6B-$15.1B；EBITDA：$5.0B-$5.3B 目标</td>
</tr>
<tr>
<td>19</td>
<td>CSL</td>
<td>$13.31B</td>
<td>$14.80B</td>
<td>+11.2%</td>
<td>CSL Behring: 14% 增长；Seqirus: 4% 增长；强劲的 NPATA 增长</td>
</tr>
<tr>
<td>20</td>
<td>Regeneron</td>
<td>$13.12B</td>
<td>$13.85B</td>
<td>+5.6%</td>
<td>Q3: 11% 增长；Dupixent 销售增长 23%；产品销售指导：$27.8B-$28.1B</td>
</tr>
</tbody>
</table>
<h3>方法论</h3>
<p>2024 年的收入预测最初基于过去四个季度报告的财务数据和公司的指导。数据来自公司报告和 finbox.com。对于提供直接指导的公司，预测与指导范围的中点对齐。对于提供增长率指导而非具体收入目标的公司，预测是根据隐含的增长范围计算的。</p>
<p>多元化公司需要针对特定细分市场进行调整，以准确估计制药收入。这些调整包括强生 63.67%、罗氏 71.6%、拜耳 33.8%、默克 KGaA37.6% 和雅培 13.0% 的细分贡献。</p>
<hr/>
<hr/>

辉瑞

礼来

诺和诺德公司

默克

<p>制药行业正在经历显著的层级变化，默克和辉瑞在 2024 财年的预计收入中处于领先地位。阿斯利康、礼来和诺和诺德公司显示出显著的增长率，表明竞争格局正在发生转变。阿斯利康在前九个月的收入增长了 19%，促使其上调了增长指引。尽管在后疫情环境中面临挑战，默克和辉瑞也保持了稳定的增长。报告概述了前 20 大制药公司的收入预测，突出了关键财务指标和增长预期</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.drugdiscoverytrends.com/wp-content/uploads/2023/04/AdobeStock_577842756-300x195.jpg" alt="" original-src="https://www.drugdiscoverytrends.com/wp-content/uploads/2023/04/AdobeStock_577842756-300x195.jpg"/></p>
<p>[sizsus/Adobe Stock]</p>
<div class="lb-trans"><p>[sizsus/Adobe Stock]</p>
</div><p>The pharmaceutical industry’s traditional hierarchy is facing its strongest challenge in years, with projected 2024 revenues showing dynamic shifts among the leaders. While Merck ($63.9B) and Pfizer ($62.5B) hold the top spots, double-digit growth from AstraZeneca (+17.9%), Eli Lilly (+33.9%), and Novo Nordisk (+26.1%) signals an accelerating transformation in the sector’s competitive landscape.</p>
<div class="lb-trans"><p>制药行业的传统层级正面临多年来最强烈的挑战，预计 2024 年的收入显示出领导者之间的动态变化。虽然默克（$63.9B）和辉瑞（$62.5B）占据了前两位，但阿斯利康（+17.9%）、礼来（+33.9%）和诺和诺德（+26.1%）的两位数增长则预示着该行业竞争格局的加速转变。</p>
</div><p>The continued strength of the GLP-1 market continues to be a market disruptor, but the medications also face complex challenges in terms of accessibility, cost, and market penetration.</p>
<div class="lb-trans"><p>GLP-1 市场的持续强劲仍然是市场的颠覆者，但这些药物在可及性、成本和市场渗透方面也面临复杂的挑战。</p>
</div><p>AstraZeneca was something of a surprise success story in a landscape where GLP-1 therapies loom large. Its strong product portfolio and performance across key therapeutic areas helped propel total revenue 19% to $39,182 million in the first nine months of the year. Oncology, Cardiovascular, Renal and Metabolism (CVRM), and Respiratory and Immunology (R&amp;I) saw growth rates of 22%, 21%, and 24% respectively, complemented by 14% growth in rare disease. Key products like Farxiga and Enhertu contributed significantly, with growth rates of 34% and 60% respectively in Q3. AstraZeneca also announced a $2 billion investment in U.S. R&amp;D and manufacturing, and navigated regulatory challenges in China. As a result, AstraZeneca upgraded its full-year 2024 guidance, projecting high teens percentage growth for both Total Revenue and Core EPS.</p>
<div class="lb-trans"><p>阿斯利康在 GLP-1 疗法占据主导地位的市场中成为了一个意外的成功故事。其强大的产品组合和在关键治疗领域的表现帮助推动了前九个月总收入增长 19%，达到 391.82 亿美元。肿瘤学、心血管、肾脏与代谢（CVRM）以及呼吸与免疫学（R&amp;I）的增长率分别为 22%、21% 和 24%，稀有疾病的增长率也达到了 14%。像 Farxiga 和 Enhertu 这样的关键产品在第三季度分别贡献了 34% 和 60% 的增长。阿斯利康还宣布在美国进行 20 亿美元的研发和制造投资，并应对了中国的监管挑战。因此，阿斯利康上调了 2024 年的全年指导，预计总收入和核心每股收益将实现高个位数的百分比增长。</p>
</div><p>Leading 2024 in terms of overall revenue areMerck &amp; Co., which continued to maintain a steady trajectory with projected worldwide sales between $63.6 billion and $64.1 billion, demonstrating approximately 5.8% to 6.6% annual growth. The company’s quarterly growth, however, has slowed, from 12% excluding foreign exchange in Q1 to 7% in Q3, indicating potential challenges even as Keytruda sales remain strong. Pfizer also continues to navigate a complex transition in a post-COVID landscape but the company had a standout third quarter despite anticipating an approximately 36% to 39% annual dip owing to decreased COVID-19 product sales.</p>
<div class="lb-trans"><p>在整体收入方面，默克公司在 2024 年继续保持稳定的轨迹，预计全球销售额在 636 亿美元到 641 亿美元之间，年增长约为 5.8% 到 6.6%。然而，该公司的季度增长已放缓，从第一季度的 12%（不包括外汇影响）降至第三季度的 7%，这表明即使 Keytruda 的销售依然强劲，仍可能面临挑战。辉瑞也在后疫情的复杂过渡中继续前行，但尽管预计由于 COVID-19 产品销售下降，年销售额将下降约 36% 到 39%，该公司在第三季度表现突出。</p>
</div><p>Here are the full projections.</p>
<div class="lb-trans"><p>以下是完整的预测。</p>
</div><table>
<thead>
<tr>
<th><strong>Rank</strong></th>
<th><strong>Company</strong></th>
<th><strong>2023 Revenue</strong></th>
<th><strong>2024 Projection</strong></th>
<th><strong>Projected Growth</strong></th>
<th><strong>Key Financial Highlights</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Merck</td>
<td>$60.12B</td>
<td>$63.85B</td>
<td>+6.2%</td>
<td>Q1-Q3: 9%, 7%, 4% growth trajectory; Strong momentum ex-FX (Q1: 12%, Q3: 7%); Guidance: $63.6B-$64.1B</td>
</tr>
<tr>
<td>2</td>
<td>Pfizer</td>
<td>$58.50B</td>
<td>$62.50B</td>
<td>+6.8%</td>
<td>Q3 showing recovery: 31% growth; COVID impact factored into guidance; Recent guidance raise: $61.0B-$64.0B</td>
</tr>
<tr>
<td>3</td>
<td>AstraZeneca</td>
<td>$45.81B</td>
<td>$54.00B</td>
<td>+17.9%</td>
<td>Consistent high-teens growth (Q1-Q3: 19%, 17%, 21%); YTD: $39.18B (+19%); Strong momentum across quarters. Guidance in the ‘high teens.’</td>
</tr>
<tr>
<td>4</td>
<td>Roche</td>
<td>$51.45B</td>
<td>$53.50B</td>
<td>+4.0%</td>
<td>Q1-Q3: Accelerating growth (2%, 5%, 9%); YTD: 6% CER growth; Mid-single-digit guidance</td>
</tr>
<tr>
<td>5</td>
<td>Johnson &amp; Johnson</td>
<td>$50.93B</td>
<td>$53.48B</td>
<td>+5.0%</td>
<td>Pharma segment steady at 5.5% growth</td>
</tr>
<tr>
<td>6</td>
<td>Sanofi</td>
<td>$46.59B</td>
<td>$52.97B</td>
<td>+13.7%</td>
<td>Accelerating growth (5.7%, 10.2%, 15.7%); Strong Q3: €13.44B; Raised EPS guidance</td>
</tr>
<tr>
<td>7</td>
<td>Novartis</td>
<td>$45.44B</td>
<td>$49.94B</td>
<td>+9.9%</td>
<td>Steady growth (7%, 9%, 10%); Low double-digit guidance; Strong operating income</td>
</tr>
<tr>
<td>8</td>
<td>Bristol-Myers Squibb</td>
<td>$45.01B</td>
<td>$47.44B</td>
<td>+5.4%</td>
<td>Consistent growth (5%, 9%, 8%); ~5% revenue growth guidance; Solid Q2 performance at 9%</td>
</tr>
<tr>
<td>9</td>
<td>Eli Lilly</td>
<td>$34.12B</td>
<td>$45.70B</td>
<td>+33.9%</td>
<td>Market leading Q2/Q3 (36%, 20%); Clear guidance: $45.4B-$46.0B; Strong momentum in key products</td>
</tr>
<tr>
<td>10</td>
<td>Novo Nordisk</td>
<td>$33.71B</td>
<td>$42.50B</td>
<td>+26.1%</td>
<td>Q3: 21% growth; Wegovy sales up 84%; Ozempic sales up 28%; Guidance: 23-27% growth</td>
</tr>
<tr>
<td>11</td>
<td>GSK</td>
<td>$37.73B</td>
<td>$40.23B</td>
<td>+6.6%</td>
<td>Strong H1 (10%, 13%); Q3 moderation to 2%; Guidance: 7-9% turnover growth</td>
</tr>
<tr>
<td>12</td>
<td>Amgen</td>
<td>$28.19B</td>
<td>$33.30B</td>
<td>+18.1%</td>
<td>Consistent 20%+ growth; Q1-Q3: 22%, 20%, 23%; Guidance: $32.8B-$33.8B</td>
</tr>
<tr>
<td>13</td>
<td>Takeda</td>
<td>$30.34B</td>
<td>$30.52B</td>
<td>+0.6%</td>
<td>Strong H1: 14.1%, 13.4% growth; Raised forecast to ¥4,480B; Better than initial flat guidance</td>
</tr>
<tr>
<td>14</td>
<td>Gilead</td>
<td>$27.12B</td>
<td>$27.95B</td>
<td>+3.1%</td>
<td>Q3: 7% growth; Key products growing (Biktarvy +13%); Guidance: $27.8B-$28.1B</td>
</tr>
<tr>
<td>15</td>
<td>Bayer AG</td>
<td>$17.78B</td>
<td>$17.23B</td>
<td>-3.0%</td>
<td>Q3 challenges: 3.6% revenue decline; EBITDA down 25.8%; Cautious 2025 outlook</td>
</tr>
<tr>
<td>16</td>
<td>Teva</td>
<td>$15.85B</td>
<td>$16.30B</td>
<td>+2.8%</td>
<td>Q3: 13% USD growth; Strong product performance; Guidance: $16.1B-$16.5B</td>
</tr>
<tr>
<td>17</td>
<td>Otsuka</td>
<td>$14.32B</td>
<td>$15.25B</td>
<td>+6.5%</td>
<td>Q3: 17% YoY growth; ¥1,730.1B forecast; Positive profit outlook</td>
</tr>
<tr>
<td>18</td>
<td>Viatris</td>
<td>$15.43B</td>
<td>$15.05B</td>
<td>-2.5%</td>
<td>Q3: 3% growth (divestiture-adjusted); Guidance: $14.6B-$15.1B; EBITDA: $5.0B-$5.3B target</td>
</tr>
<tr>
<td>19</td>
<td>CSL</td>
<td>$13.31B</td>
<td>$14.80B</td>
<td>+11.2%</td>
<td>CSL Behring: 14% growth; Seqirus: 4% growth; Strong NPATA growth</td>
</tr>
<tr>
<td>20</td>
<td>Regeneron</td>
<td>$13.12B</td>
<td>$13.85B</td>
<td>+5.6%</td>
<td>Q3: 11% growth; Dupixent sales +23%; Product sales guidance: $27.8B-$28.1B</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>排名</strong></th>
<th><strong>公司</strong></th>
<th><strong>2023 年收入</strong></th>
<th><strong>2024 年预测</strong></th>
<th><strong>预计增长</strong></th>
<th><strong>关键财务亮点</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>默克</td>
<td>$60.12B</td>
<td>$63.85B</td>
<td>+6.2%</td>
<td>Q1-Q3: 9%, 7%, 4% 增长轨迹；剔除外汇影响的强劲势头（Q1: 12%, Q3: 7%）；指导：$63.6B-$64.1B</td>
</tr>
<tr>
<td>2</td>
<td>辉瑞</td>
<td>$58.50B</td>
<td>$62.50B</td>
<td>+6.8%</td>
<td>Q3 显示恢复：31% 增长；COVID 影响已纳入指导；最近的指导上调：$61.0B-$64.0B</td>
</tr>
<tr>
<td>3</td>
<td>阿斯利康</td>
<td>$45.81B</td>
<td>$54.00B</td>
<td>+17.9%</td>
<td>一致的高个位数增长（Q1-Q3: 19%, 17%, 21%）；年初至今：$39.18B (+19%); 各季度强劲势头。指导在 “高个位数” 范围内。</td>
</tr>
<tr>
<td>4</td>
<td>罗氏</td>
<td>$51.45B</td>
<td>$53.50B</td>
<td>+4.0%</td>
<td>Q1-Q3: 加速增长（2%, 5%, 9%）；年初至今：6% CER 增长；中个位数指导</td>
</tr>
<tr>
<td>5</td>
<td>强生</td>
<td>$50.93B</td>
<td>$53.48B</td>
<td>+5.0%</td>
<td>制药部门稳定在 5.5% 增长</td>
</tr>
<tr>
<td>6</td>
<td>赛诺菲</td>
<td>$46.59B</td>
<td>$52.97B</td>
<td>+13.7%</td>
<td>加速增长（5.7%, 10.2%, 15.7%）；强劲的 Q3：€13.44B；上调每股收益指导</td>
</tr>
<tr>
<td>7</td>
<td>诺华</td>
<td>$45.44B</td>
<td>$49.94B</td>
<td>+9.9%</td>
<td>稳定增长（7%, 9%, 10%）；低双位数指导；强劲的营业收入</td>
</tr>
<tr>
<td>8</td>
<td>百时美施贵宝</td>
<td>$45.01B</td>
<td>$47.44B</td>
<td>+5.4%</td>
<td>一致增长（5%, 9%, 8%）；~5% 收入增长指导；Q2 表现稳健，增长 9%</td>
</tr>
<tr>
<td>9</td>
<td>礼来</td>
<td>$34.12B</td>
<td>$45.70B</td>
<td>+33.9%</td>
<td>市场领先的 Q2/Q3（36%, 20%）；明确的指导：$45.4B-$46.0B；关键产品强劲势头</td>
</tr>
<tr>
<td>10</td>
<td>诺和诺德</td>
<td>$33.71B</td>
<td>$42.50B</td>
<td>+26.1%</td>
<td>Q3: 21% 增长；Wegovy 销售增长 84%；Ozempic 销售增长 28%；指导：23-27% 增长</td>
</tr>
<tr>
<td>11</td>
<td>GSK</td>
<td>$37.73B</td>
<td>$40.23B</td>
<td>+6.6%</td>
<td>强劲的上半年（10%, 13%）；Q3 放缓至 2%；指导：7-9% 营业额增长</td>
</tr>
<tr>
<td>12</td>
<td>安进</td>
<td>$28.19B</td>
<td>$33.30B</td>
<td>+18.1%</td>
<td>一致的 20%+ 增长；Q1-Q3: 22%, 20%, 23%；指导：$32.8B-$33.8B</td>
</tr>
<tr>
<td>13</td>
<td>武田</td>
<td>$30.34B</td>
<td>$30.52B</td>
<td>+0.6%</td>
<td>强劲的上半年：14.1%, 13.4% 增长；上调预测至¥4,480B；优于最初的平稳指导</td>
</tr>
<tr>
<td>14</td>
<td>吉利德</td>
<td>$27.12B</td>
<td>$27.95B</td>
<td>+3.1%</td>
<td>Q3: 7% 增长；关键产品增长（Biktarvy +13%）；指导：$27.8B-$28.1B</td>
</tr>
<tr>
<td>15</td>
<td>拜耳</td>
<td>$17.78B</td>
<td>$17.23B</td>
<td>-3.0%</td>
<td>Q3 挑战：3.6% 收入下降；EBITDA 下降 25.8%；谨慎的 2025 年展望</td>
</tr>
<tr>
<td>16</td>
<td>Teva</td>
<td>$15.85B</td>
<td>$16.30B</td>
<td>+2.8%</td>
<td>Q3: 13% 美元增长；强劲的产品表现；指导：$16.1B-$16.5B</td>
</tr>
<tr>
<td>17</td>
<td>大冢</td>
<td>$14.32B</td>
<td>$15.25B</td>
<td>+6.5%</td>
<td>Q3: 同比增长 17%；¥1,730.1B 预测；积极的利润展望</td>
</tr>
<tr>
<td>18</td>
<td>Viatris</td>
<td>$15.43B</td>
<td>$15.05B</td>
<td>-2.5%</td>
<td>Q3: 3% 增长（剔除剥离影响）；指导：$14.6B-$15.1B；EBITDA：$5.0B-$5.3B 目标</td>
</tr>
<tr>
<td>19</td>
<td>CSL</td>
<td>$13.31B</td>
<td>$14.80B</td>
<td>+11.2%</td>
<td>CSL Behring: 14% 增长；Seqirus: 4% 增长；强劲的 NPATA 增长</td>
</tr>
<tr>
<td>20</td>
<td>Regeneron</td>
<td>$13.12B</td>
<td>$13.85B</td>
<td>+5.6%</td>
<td>Q3: 11% 增长；Dupixent 销售增长 23%；产品销售指导：$27.8B-$28.1B</td>
</tr>
</tbody>
</table>
</div><h3>Methodology</h3>
<div class="lb-trans"><h3>方法论</h3>
</div><p>The revenue projections for 2024 were initially based on financial figures derived from the trailing four quarters of reported revenue and from the companies’ guidance. Data from company reports and finbox.com. For companies offering direct guidance, projections were aligned with the midpoint of the guidance ranges. For companies providing growth-rate guidance rather than specific revenue targets, projections were calculated using the implied growth ranges.</p>
<div class="lb-trans"><p>2024 年的收入预测最初基于过去四个季度报告的财务数据和公司的指导。数据来自公司报告和 finbox.com。对于提供直接指导的公司，预测与指导范围的中点对齐。对于提供增长率指导而非具体收入目标的公司，预测是根据隐含的增长范围计算的。</p>
</div><p>Diversified companies required segment-specific adjustments to accurately estimate pharmaceutical revenue. These adjustments included segment contributions of 63.67% for Johnson &amp; Johnson, 71.6% for Roche, 33.8% for Bayer, 37.6% for Merck KGaA, and 13.0% for Abbott.</p>
<div class="lb-trans"><p>多元化公司需要针对特定细分市场进行调整，以准确估计制药收入。这些调整包括强生 63.67%、罗氏 71.6%、拜耳 33.8%、默克 KGaA37.6% 和雅培 13.0% 的细分贡献。</p>
</div><hr/>
<div class="lb-trans"><hr/>
</div><hr/>
<div class="lb-trans"><hr/>
</div>

Projecting the top 20 Big Pharma firms of FY2024

- 制药行业面临激烈竞争，2024 年收入预测显示领导者动态变化。  
- 阿斯利康、礼来和诺和诺德的增长率分别为 17.9%、33.9% 和 26.1%。  
- 阿斯利康预计 2024 年总收入和核心每股收益将实现高单位数增长。  

预测 2024 财年排名前 20 的大型制药企业